DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment

BACKGROUND: The commercial formulation of sumatriptan nasal spray is an effective option for migraine patients requiring or preferring a non-oral route of drug administration, but its utility is limited by poor absorption and tolerability issues. DFN-02, a new formulation of sumatriptan 10 mg nasal...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipton, Richard B., Munjal, Sagar, Brand-Schieber, Elimor, Rapoport, Alan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441104/
https://www.ncbi.nlm.nih.gov/pubmed/30877622
http://dx.doi.org/10.1007/s40263-019-00614-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441104/
https://www.ncbi.nlm.nih.gov/pubmed/30877622
http://dx.doi.org/10.1007/s40263-019-00614-6

Ejemplares similares